Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 23:27:92.
doi: 10.4103/jrms.jrms_895_21. eCollection 2022.

Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns

Maliheh Hamidian  1 , Ramin Ansari  2 , Mohammad Mehdi Zarshenas  3   4 , Farzaneh Foroughinia  1
Affiliations
Review

Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns

Maliheh Hamidian et al. J Res Med Sci. .

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has rapidly spread worldwide and has been infected more than 219 million individuals with 4.55 million deaths worldwide as of September 2021, causing a pandemic. Preexisting cardiovascular (CV) comorbidities such as hypertension, diabetes, and coronary artery disease seem to be associated with greater severity of infection, worse prognosis, and higher mortality. Moreover, COVID-19 can contribute to CV complications, including acute myocardial injury, arrhythmia, acute coronary syndrome, and venous thromboembolism, emphasizing the importance of precocious detection and implementation of optimal therapeutic strategies. This review provides an overview of evidence-based data of CV complications of COVID-19, focusing on their management strategies, as well as potential cardiac adverse effects and drug interactions, due to off-label and investigational drugs used for the treatment of COVID-19.

Keywords: Adverse effects; complications; coronavirus disease 2019; disease management; heart.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Management of cardiovascular complications
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Allergy Clin Immunol. 2020;146:110–8. - PMC - PubMed
    1. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158:1831–3.e3. - PMC - PubMed
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020;323:1061–9. - PMC - PubMed
    1. Ziyaeifard M, Ziyaeifard P. Cardiac anesthesia and COVID-19 outbreak: What should we know? J Res Med Sci. 2020;25:89. - PMC - PubMed
    1. Nayeri ND, Nadali J, Divani A, Basirinezhad MH, Meidani M. Clinical manifestation, laboratory and radiology finding, treatment and outcomes of COVID-19: A systematic review and meta-analysis. J Res Med Sci. 2021;26:41. - PMC - PubMed

LinkOut - more resources